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Methods: The national cancer registration and hospital discharge data for women in England
(1998–2007) were linked, and the records for Hodgkin lymphoma, melanoma and breast can-
cer were indexed as to whether women had delivered a child in separate time periods prior to
their cancer diagnosis. Survival analyses were conducted in order to characterise prognosis in
relation to childbirth, with statistical adjustment for age and (where possible) stage.
Findings: For melanoma and breast cancer, survival was strongly reduced in women who gave
birth in the year prior to cancer diagnosis. The age-adjusted hazard ratios (HR) with 95% con-
ﬁdence intervals (CI) were 2.06 (1.42–3.01) for melanoma and 1.84 (1.64–2.06) for breast can-
cer. The associations were only slightly attenuated by further adjustment for tumour stage.
For breast cancer, the excess death rate in women with a recent childbirth peaked at 2 years
and remained elevated for 6 to 8 years. Previous childbirth had no overall effect on the out-
come of Hodgkin lymphoma.hed by Elsevier Ltd.
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H. Møller et al. / European Journal of Cancer 49 (2013) 3686–3693 3687Interpretation: Melanoma and breast cancer prognosis are adversely affected by recent gesta-
tion and childbirth in a way that is not due to stage of the cancer, but rather to inherent bio-
logical properties of the tumours. Possible biological mechanisms include immunosuppression
(melanoma), the hormonal milieu in gestation and a tumour promoting microenvironment
post-partum (breast cancer).
 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Two of the authors of this paper care for patients
with haematological malignancies. They had observed
advanced or fatal cases in women diagnosed with Hodg-
kin lymphoma within a few years after childbirth, and
hypothesised that recent childbirth is associated with
poor prognosis.
We explored this hypothesis using a linked dataset of
English cancer registrations and hospital discharge
records. To compare with two other malignancies for
which studies of the same hypotheses have been done,
we analysed the association between recent childbirth
and survival after cancer diagnosis in women with mel-
anoma of the skin or breast cancer, two of the most
common cancers in women of childbearing age.
Hodgkin lymphoma is the most common lymphoma
in women of childbearing age.1 Several studies have
examined the occurrence of Hodgkin lymphoma in rela-
tion to childbirth and parity.2,3 The results are consis-
tent with a moderately protective eﬀect of parity on
Hodgkin lymphoma risk, but a similar association was
seen in males as well as in females, and may be attribut-
able to confounding by socio-economic factors. The sur-
vival of Hodgkin lymphoma diagnosed during
pregnancy has been reported to be similar to non-preg-
nant women,4 but the evidence base on prognosis is lim-
ited. One study found higher survival with increasing
parity.2 The magnitude of the mortality reduction was
similar in women and men. A large study from Norway
found no diﬀerence in cause-speciﬁc survival from lym-
phoma and leukaemia in patients diagnosed in preg-
nancy or while lactating.5
The incidence of melanoma of the skin has no consis-
tent association with a woman’s parity.6,7 The inﬂuence
of reproductive history on prognosis remains unclear.
Case studies have described patients with rapidly grow-
ing melanoma during pregnancy, but recent reviews
have concluded that melanoma prognosis does not
appear to be aﬀected by pregnancy.8,9 Large, popula-
tion-based studies on progression and prognosis in mel-
anoma in relation to pregnancy and childbirth have
shown inconsistent results5,10–12 and the general consen-
sus is that pregnancy or recent childbirth does not aﬀect
the prognosis in clinically localised melanoma of the
skin.8,10–12 An open question remains about the progno-
sis in non-localised melanoma, and to the independent
and joint eﬀects of reproductive history and tumourcharacteristics such as anatomic location, thickness
and stage of disease.13
Breast cancer incidence has strong associations with
reproductive characteristics of the woman. Childbirth
conveys a long-term reduction in the incidence of the
most common types of breast cancer14 despite a tran-
sient, short-term increase in incidence.15 Pregnancy-
associated breast cancers, deﬁned as cancers diagnosed
during pregnancy or in the year following childbirth,
are known to have an adverse prognosis,16–20 but there
is uncertainty about the biological basis and the patho-
logical correlates of this association.21
2. Materials and methods
2.1. Patient data
From the cancer registration dataset for the England
population, we extracted records for women aged 10–
54 years, diagnosed in 1998–2007 with Hodgkin lym-
phoma (3603 cases), melanoma of the skin (16,528)
and breast cancer (110,943).
In the linked hospitals’ admission data we extracted
episodes relating to an obstetric event (ICD10 codes
O00 to O99 or OPCS4 surgery codes starting with Q
or R) or relating to reproduction (Z codes between
Z30 and Z39) in the diagnosis and operation ﬁelds of
the hospital discharge dataset. These were further exam-
ined to identify those which related to labour, delivery,
postpartum care and/or childbirth.
Each cancer registration record was then indexed to
indicate whether childbirth had or had not happened
in diﬀerent time-windows prior to the time of cancer
diagnosis: childbirth within 1 year before the diagnosis
(0–1), in the second full year before diagnosis (1–2),
etc., up to the 5th year before diagnosis. All recorded
childbirths for each woman were used and these indices
were analysed separately. We used Cox’s proportional
hazard regression to estimate the hazard ratio for having
(versus not having) given birth in each interval. The
regression analyses were adjusted for age. Follow-up
was to the end of 2008, giving a maximum duration of
follow-up of 11 years (1998–2008).2.2. Analysis
In order to visualise the main results for breast can-
cer, we plotted Kaplan–Meier survival functions for
3688 H. Møller et al. / European Journal of Cancer 49 (2013) 3686–3693two groups of women: those who had given birth in the
year before their breast cancer diagnosis and those who
had not.
To give an appreciation of the age-speciﬁcity and per-
sistence of the eﬀect of recent childbirth in breast cancer,
we modelled the absolute hazard of death as a function of
age and time since breast cancer diagnosis, using ﬂexible
parametric survival models. The baseline hazards were
modelled using splineswith four degrees of freedom (three
interval and two boundary knots); while the time varying
eﬀects of log (age) and time since diagnosis used splines
with three degrees of freedom. The estimated hazards
were plotted for three values of age at diagnosis (25, 35
and 45 years) for the interval of follow-up from breast
cancer diagnosis and up to 10 years thereafter.
We attempted to assign a tumour-node-metastasis
(TNM) stage to all breast cancer cases on the basis of
available stage data and data on tumour size, aﬀected
lymph nodes and metastasis. Using all the available
data, 87.5% of breast cancers had a valid assigned
TNM. The assigned TNM stage for breast cancer was
used to pursue a stage-adjusted Cox proportional haz-
ards regression analysis, and stratiﬁed, stage-speciﬁc
Kaplan–Meier survival analysis.
Similarly, we used available data for melanoma to
assign a TNM stage in 72% of the cases, and we repeated
the Cox proportional regression analysis with adjustment
for stage.Wewere not able to extract data ondisease stage
or prognostic indices in Hodgkin lymphoma.
3. Results
3.1. Hodgkin lymphoma
Table 1 shows the results of the Cox proportional
hazard analysis. For women with Hodgkin lymphomaTable 1
Hazard ratios for death in female Hodgkin’s lymphoma patients in relatio
Period before cancer
diagnosis (years)
Total number of
women
Number with
childbirth
0 to 1 3603 138
1 to 2 3246 105
2 to 3 2894 81
3 to 4 2534 68
4 to 5 2183 54
Table 2
Hazard ratios for death in female melanoma patients in relation to childb
Period before cancer
diagnosis (years)
Total number of
women
Number with
childbirth
0 to 1 16,528 306
1 to 2 15,229 267
2 to 3 13,923 225
3 to 4 12,458 229
4 to 5 10,829 201
Note: the estimate of 2.06 changed to 1.92 (1.32–2.79) with adjustment forthere were 3603 women in the analysis of childbirth in
the recent year before cancer diagnosis, of which 138
had given birth. Among the latter, ten died within the
course of follow-up. The hazard ratio of 0.96 (95% con-
ﬁdence interval 0.51–1.82) indicate that childbirth within
1 year before Hodgkin lymphoma diagnosis had no sta-
tistically signiﬁcant or clinically relevant association
with the subsequent prognosis.
For childbirth in the two proceeding intervals before
Hodgkin lymphoma diagnosis there was a marginally
higher than expected death rate associated with child-
birth in the interval 1–2 years before cancer diagnosis
(1.42; 0.75–2.70), and a lower than expected death rate
with childbirth in the interval 2–3 years before cancer
diagnosis (0.15; 0.02–1.05). In total, 32 deaths occurred
and the expected value was 32.3.
3.2. Melanoma
For melanoma of the skin there was a two-fold death
rate for women who had given birth within 1 year before
the cancer diagnosis (2.06; 1.42–3.01) (Table 2), but no
signiﬁcant association with childbirth more distant from
the time of diagnosis. We reviewed the clinical informa-
tion in the cancer registry for the 29 women who gave
birth in the year prior to the diagnosis and who died
during the course of follow-up. Of these, 16 women
had stage 1 or 2 when diagnosed, six had stage 3 or 4,
and seven could not be staged. Twenty-ﬁve deaths were
due to melanoma and four deaths were from another or
an unknown cause. Their median survival time was
722 days (quartile range: 468–1336 days).
With adjustment for TNM stage, the hazard ratio
estimate of 2.06 (1.42–3.01) for women with childbirth
in the year prior to the melanoma changed to 1.92
(1.32–2.79).n to childbirth in diﬀerent periods before the cancer diagnosis.
Deaths in women with
childbirth
Hazard ratio, age-
adjusted
95% conﬁdence
interval
10 0.96 0.51 1.82
10 1.42 0.75 2.70
1 0.15 0.02 1.05
5 1.09 0.44 2.66
6 1.69 0.74 3.88
irth in diﬀerent periods before the cancer diagnosis.
Deaths in women with
childbirth
Hazard ratio, age-
adjusted
95% conﬁdence
interval
29 2.06 1.42 3.01
15 1.22 0.73 2.05
11 1.14 0.62 2.08
13 1.33 0.76 2.32
9 1.18 0.61 2.30
stage.
Table 3
Hazard ratios for death in female breast cancer patients in relation to childbirth in diﬀerent periods before the cancer diagnosis.
Period before cancer
diagnosis (years)
Total number of
women
Number with
childbirth
Deaths in women with
childbirth
Hazard ratio, age-
adjusted
95% conﬁdence
interval
0 to 1 110,943 1014 316 1.84 1.64 2.06
1 to 2 100,062 1068 204 1.09 0.95 1.26
2 to 3 88,800 1143 219 1.26 1.10 1.45
3 to 4 77,502 1162 209 1.38 1.20 1.59
4 to 5 66,278 1120 153 1.16 0.99 1.36
Note: the estimate of 1.84 changed to 1.68 (1.50–1.88) with adjustment for stage.
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Fig. 1. Kaplan–Meier survival functions for women with breast cancer
who had (red) a childbirth in the year prior to diagnosis, or who had
no birth in that interval (black).
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Fig. 2. Estimates of the absolute hazard of death (rate of death per person-
cancer who had (red) a childbirth in the year prior to diagnosis, or who had
are plotted for three ﬁxed values of age. Ninety-ﬁve percent conﬁdence int
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For breast cancer there was a substantial and statisti-
cally signiﬁcant excess death rate in women who had
given birth within 1 year before the diagnosis with breast
cancer (hazard ratio 1.84; 1.64–2.06) (Table 3). Smaller,
but statistically signiﬁcant increases in the death rate
were seen for women who had delivered in the periods
from 1 to 4 years before cancer diagnosis. For delivery
in the most distant period before diagnosis (4 to 5 years
before cancer diagnosis), the survival eﬀect had waned
to 1.16 (0.99–1.36).
We repeated this analysis in the subset of women in
the narrower age-range 25–34 years and found similar
results.
The Kaplan–Meier plot (Fig. 1) shows the cumulative
eﬀect of childbirth in the recent year before diagnosis of
breast cancer. The eﬀect on survival was evident from
less than 1 year after diagnosis and the diﬀerence built
up gradually up to three to 4 years after diagnosis. years 45 years
No childbirth within one year
0.0
0.05
0.10
0.15
6 8 10
ce diagnosis
0 2 4 6 8 10
Years since diagnosis
year) from a ﬂexible parametric survival model for women with breast
no birth in that interval (black). The model includes age and estimates
ervals are indicated for women with a recent childbirth.
3690 H. Møller et al. / European Journal of Cancer 49 (2013) 3686–3693The modelled hazard of death (Fig. 2) shows that the
absolute hazard of death in breast cancer patients was
slightly higher in young women, both in those who gave
birth in the recent year and in those who did not. Within
each age-speciﬁc analysis, there was a gradual increase
up to a doubling of the hazard of death associated with
recent childbirth around 2 years after cancer diagnosis.
In the analysis ﬁxed at 25 years of age, the two hazard
functions tended to separate again from 4 to 10 years
into follow-up, but judging from the 95% conﬁdence
intervals, that diﬀerence was not statistically signiﬁcant.
In the older age groups, the hazards decreased gradually
from about 1 year and onwards and at 6 to 8 years
after diagnosis there was no longer any important
diﬀerence between women who gave birth in the year
before their breast cancer diagnosis and women who
did not.Table 4
Distribution of imputed tumour-node-metastasis (TNM) stage in 1014 w
109,929 women without a childbirth in this interval.
TNM stage With childbirth in (0 to 1) year interval
N % % excl NA
1 183 18 21
2 505 50 59
3 100 10 12
4 65 6 8
NA 161 16 –
Total 1014 100 100
0 2 4 6 8 10
Years since diagnosis
33994 30102 22729 15865 9323 2945 51330 43999 31148 20513 11259 3530 7987 6213
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Fig. 3. Kaplan–Meier survival functions, stratiﬁed by stage, for women with
or who had no birth in that interval (black).Table 4 shows the distribution of TNM stage in
women with and without childbirth in the year before
breast cancer diagnosis. The proportions of women
where a stage could be assigned were similar (84% versus
87%). Among women where a stage could be assigned,
the stage distribution was unfavourable in women with
recent childbirth: stage 1: 21% versus 35%; stage 2 or
higher: 79% versus 65%.
With adjustment for TNM stage, the hazard ratio esti-
mate of 1.84 (1.64–2.06) for women with childbirth in the
year prior to breast cancer diagnosis did not change
much. The stage-adjusted estimate was 1.68 (1.50–1.88).
Fig. 3 shows the Kaplan–Meier survival functions
separately for TNM stages 1–4 and for the unstaged
cases. Regardless of stage, the survival was worse in
women with recent childbirth before breast cancer
diagnosis.omen with childbirth in the year before breast cancer diagnosis and
Without childbirth in (0 to 1) year interval
N % % excl NA
33,994 31 35
51,330 47 54
7987 7 8
2856 3 3
13,762 13 –
109,929 100 100
3971 2340 1239 339 2856 1518 772 406 213 63 13762 11518 8644 5901 3729 1181
36 15 5 0 65 28 6 3 2 0 161 118 80 50 28 2
Stage III Stage IV Stage missing
Childbirth within one year
4 6 8 10
 since diagnosis
0 2 4 6 8 10
Years since diagnosis
0 2 4 6 8 10
Years since diagnosis
breast cancer who had (red) a childbirth in the year prior to diagnosis,
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4.1. Deﬁnition of pregnancy-associated cancer
We considered as a pregnancy-associated cancer case
only women who had a recent childbirth (within 1 to
5 years) when they were diagnosed with cancer due to
several reasons: Firstly, our only means of identifying
women with pregnancy-associated cancer was a linkage
to information about a completed pregnancy and child-
birth taking place in a hospital. No national data allow
for pregnancies to be assigned to cancer registration
records. Secondly, the inclusion of pregnancy-associated
cancer deﬁned by pregnancy and not by childbirth
would lead to the inclusion of pregnancies that were
subsequently terminated. Thirdly, the treatment for can-
cer patients may diﬀer if the patient is pregnant and any
diﬀerence in survival could be due to diﬀerences in treat-
ments rather than the physiology associated with preg-
nancy and childbirth. With this deﬁnition of
pregnancy-associated cancer, our results do not apply
to clinical questions of management of cancer during
pregnancy, or to implications of a pregnancy in a person
who had cancer in the past.4.2. Interpretation of the data on Hodgkin lymphoma
Our results suggest that recent childbirth does not
inﬂuence survival from Hodgkin lymphoma. Despite
the large study population, the number of women with
Hodgkin lymphoma and a recent childbirth was small,
and the number of deaths among those women was only
32, implying high statistical uncertainty. In the analysis
of childbirth in the year before Hodgkin lymphoma
diagnosis (i.e. the interval where strong signals were
detected for melanoma and breast cancer), the estimate
of 0.96 implies no association, but the 95% conﬁdence
interval of 0.51–1.82 is consistent with a range of
estimates.4.3. Interpretation of the data on melanoma
We found a large and statistically signiﬁcant excess
mortality in melanoma patients diagnosed within a year
after childbirth. Most of these women had stage 1 or 2
melanoma, the median survival was more than 2 years,
and the cause of death registered was malignant mela-
noma. After adjustment for stage an almost two-fold
increased mortality rate remained.
This result counters the prevailing assessment of no
or little association between pregnancy, childbirth and
melanoma prognosis but several reports have observed
an adverse stage-distribution in pregnancy associated
melanoma.22,23
It can be debated whether stage should be adjusted
for in the analysis of pregnancy-associated melanomaand survival. Some authors (e.g. Ref.11) consider that
such adjustment is natural and necessary, others (e.g.
Refs.24,25) emphasise the stage-adjusted and the unad-
justed analysis address two diﬀerent questions of causa-
tion, both of which are clinically relevant. The
unadjusted analysis allows for stage to be a mechanism
whereby pregnancy and childbirth adversely aﬀects sur-
vival. A delay in diagnosis or a more aggressive type of
melanoma could both contribute to this association. The
stage-adjusted analysis aims to eliminate the intermedi-
ate eﬀect of advanced stage and addresses more directly
the question of the stage-independent malignant poten-
tial of the cancer. Our results suggest that the increased
mortality of melanoma patients with a recent childbirth
is mainly due to a stage-independent casual pathway.
There is no evident biological mechanism. One possi-
bility is that pregnancy is associated with immune sup-
pression and an immunosuppressed state permits some
melanomas with high malignant potential to progress
and come to clinical diagnosis in the short term follow-
ing a childbirth. Consistent with this hypothesis, several
studies have shown increased case-fatality in melanoma
in immunosuppressed patients, regardless of the stage of
the melanoma.26,274.4. Interpretation of the data on breast cancer
Pregnancy and childbirth provokes a transient wave
of excess occurrence of breast cancer, and this excess
is largest in older, uniparous women and maximal
immediately after the childbirth, where after it decreases
over the following 10–15 years.15 Many studies have
established that these pregnancy-associated breast can-
cers have a relatively poor prognosis.16–21,25
The stage-stratiﬁed and stage-adjusted analyses of our
data show that in this population the adverse prognosis of
pregnancy-associatedbreast cancer is largely independent
of stage, and manifest also in localised and otherwise
good-prognosis cancers. The implication is that the breast
carcinogenic processes facilitated by the pregnancy lead
to inherently more aggressive forms of breast cancer.
In addition to stage-independent phenomena, the
stage distribution gives indication of a less favourable
stage distribution in pregnancy-associated breast can-
cers. Firstly, breast cancer that occurs in the post-par-
tum period and during lactation may be diagnosed
with delay, for example if the cancer masquerades as
mastitis.28 Secondly, more advanced stage-distribution
may be secondary to the more aggressive, and plausibly
faster growing, biological phenotype. We are not able to
assess the relative contributions of diagnostic delay and
biological aggressiveness to the adverse stage-distribu-
tion. There are probably combined reasons for the more
advanced stage distribution in pregnancy-associated
breast cancers, where biological mechanisms, delay of
diagnosis due to delay of seeking medical consultation
3692 H. Møller et al. / European Journal of Cancer 49 (2013) 3686–3693and/or suboptimal diagnostic procedures may be con-
tributing factors. Results consistent with these were
recently published from Sweden.25
The excess mortality manifests very shortly, if not
immediately, after breast cancer diagnosis and rise to a
maximum around 2 years after diagnosis. Further,
whereas the adverse prognosis is strongest in women with
childbirth within 1 year prior to the breast cancer diagno-
sis, there is also an indication of less strong mortality
increase inwomenwith longerduration (up to4 to5 years)
betweenchildbirthandbreast cancerdiagnosis.Theexcess
mortality decays thereafter, and 6 to 8 years after diagno-
sis, there isno longeranyexcess riskofbreast cancerdeath.
4.5. Limitations of the study
We lack stage information in women with Hodgkin
lymphoma. Our classiﬁcation of melanoma and breast
cancer stage was retrospective and based on incomplete
data in the cancer registry. The accuracy of this
stage information is lower than stage data assigned
prospectively in a standardised way. The routine cancer
registration data do not permit classiﬁcation of histo-
pathological type of breast cancer. Such information
may have given information about the biological nature
of pregnancy associated breast cancers in terms of e.g.
basal type characteristics or triple-negativity.
4.6. Implications for population health and clinical
practice in oncology
In many developed countries, there has been a trend
towards postponement of reproduction and childbirth.
The incidence rates of most cancers increase with age,
and postponement of childbirth therefore leads to an
increase in the rate of pregnancy-associated cancers.29
Carers of patients with melanoma or breast cancer
should be aware of the increased risk of death in women
who are diagnosed within a few years after having a
child, including those patients who had small and local-
ised cancers, normally associated with very good prog-
nosis. This knowledge may have implications for
guidelines for follow-up for women with a recent child-
birth. Women with breast cancer and a recent childbirth
may be assured that the excess risk of death is a tran-
sient phenomenon which wanes over the course of 6 to
8 years after the breast cancer diagnosis.Conﬂict of interest statement
None declared.
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